Treatment for cancer-associated superficial vein clots
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
This project will see if different blood-thinning treatments given to adults with active cancer and recent superficial vein clots lead to better outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1576 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Amiens) |
| Trial ID | NCT07210671 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational cohort at CHU Amiens enrolling adults with Doppler-confirmed superficial venous thrombosis and active cancer. Investigators will record which anticoagulant regimens clinicians choose in routine care for SVT diagnosed within the prior month. Patients will be followed for clinical outcomes such as clot progression, new deep vein thrombosis or pulmonary embolism, bleeding events, and changes in therapy. The collected data will be used to describe associations between real-world treatment choices and patient outcomes to inform future recommendations.
Who should consider this trial
Good fit: Adults (18+) with active cancer and a Doppler-confirmed superficial venous thrombosis within the past month who speak French and have social security coverage are ideal candidates.
Not a fit: Patients with concomitant pulmonary embolism or proximal/deep vein thrombosis, those already on anticoagulation for another reason, legally protected adults, or those with contraindications to anticoagulation are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, results could help doctors choose safer and more effective anticoagulation for cancer patients with superficial vein clots.
How similar studies have performed: Randomized trials have established anticoagulation approaches for cancer-associated deep vein thrombosis, but prospective data specifically on cancer-associated superficial venous thrombosis are sparse and largely lacking.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 * Patient affiliated to a social security scheme * Patient who understands French * Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old. * Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery) Exclusion Criteria: * Patients under legal protection * Patients with concomitant pulmonary embolism * Patient with proximal or distal deep vein thrombosis * Patient treated with anticoagulant therapy for another indication * Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding. * Patient opposed to participation in research
Where this trial is running
Amiens
- CHU Amiens — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Simon SOUDET, Dr
- Email: soudet.simon@chu-amiens.fr
- Phone: 33+3 22 08 80 51
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.